Brought to you by 
UCB teams up with Five Prime to discover inflammatory disease/CNS disorder treatments
19 Oct 2021
Executive Summary
Biotech Five Prime Therapeutics Inc. will use its drug discovery platforms on up to five of UCB Group’s programs to identify targets and mechanisms in the areas of fibrosis-related inflammatory and CNS disorders.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
UCB teams up with Five Prime to discover inflammatory disease/CNS disorder treatments
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice